Pharmaceutical giant Pfizer Ltd reported robust figures for the first quarter ended June 30, 2025, with a 27.2% year-on-year rise in net profit to ₹191.7 crore, compared with ₹150.7 crore a year earlier.
Revenue grew 7.1% to ₹604 crore from ₹563 crore, while EBITDA increased 18.1% to ₹209.7 crore from ₹177.6 crore in Q1FY25.
Margins improved to 34.8% for the quarter ended June 30, 2025, from 31.5% in the same quarter last year.
#1QWithCNBCTV18 | Pfizer report its #Q1Results ;
????Net Profit Up 27.2% At ₹191.7 Cr Vs ₹150.7 Cr (YoY)????Revenue Up 7.1% At ₹604 Cr Vs ₹563 Cr (YoY)????EBITDA Up 18.1% At ₹209.7 Cr Vs ₹177.6 Cr (YoY)
????Margin At 34.8% Vs 31.5% (YoY) pic.twitter.com/wzl8Vu91vI
— CNBC-TV18 (@CNBCTV18Live) August 13, 2025
“During the quarter ended June 30, 2025, the company had received requisite approvals from MIDC to assign and assume the lease of MIDC land and sale of building constructed on such land and has completed the transfer and sale of said assets,” Pfizer said in a release.
This transaction led to a net gain of ₹172.81 crore (after deducting the carrying value of approximately ₹31.75 crore and the cost to sell, premium and other charges of ₹59.84 crore, net of recovery), which was reported under ‘exceptional Items.’
Next gen vaccine
Earlier on August 11, the company announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. With broader serotype coverage, Pfizer’s vaccine marks a significant advancement in protection against pneumococcal disease in adults.
Meenakshi Nevatia, Managing Director of the company in India, said, “We are excited to launch PCV20, our 20-valent pneumococcal conjugate vaccine, in India. We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunisation in our country.”
Also Read: GSTAT orders Subway franchisee to deposit ₹5.45 lakh profiteering amount with interest
Shares of Pfizer Ltd ended higher on Wednesday (August 13) by 0.18% at ₹5,096.25 on the NSE.
(Edited by : Shoma bhattacharjee)
